AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03292861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: 125 mg IV methylprednisolone immediately post-operatively x 3 doses q12hrs, then switching to oral prednisone at 1.0 mg/kg/day po divided into bid doses that are rounded off to the next higher 5 mg increment. For example, a 76 kg person would should be dosed at 38 mg po bid, which rounded off to the next 5 mg increment would be 40 mg po bid. (Equivalent dosing via an alternative route may be used if pos not tolerated or contraindicated). Prednisone will be tapered by 10 mg qd until the dose of 10 mg po bid is reached.
Study NCT00377247 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous monocyte-derived dendritic cells (DC) transfected with DNA
Description: The patients will receive 1 x 107 DC/vaccine delivered intranodally or perinodally to lymph nodes (LN) distant from the head and neck area (e.g., to inguinal LN)
Study NCT01774110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early standardized task training
Description: Early standardized task training is a treatment approach using treadmill training applied very early after stroke onset.
Study NCT00640016 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.
Study NCT00640016 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAT-354 1 mg/kg
Description: CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
Study NCT00640016 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAT-354 5 mg/kg
Description: CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
Study NCT02551939 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Fat Grafting
Description: Autologous Fat Grafting
Study NCT02643914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Study NCT02643914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Compatible Nicotine Delivery Device
Study NCT01626469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Captopril
Description: 25mg Captopril
Study NCT01626469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Captopril
Description: 25mg Captopril
Study NCT01626469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01626469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00651690 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: 200 U to 360 U of botulinum toxin Type A on Day 0. Patients who met retreatment criteria received a second treatment (open-label) at Week 12 or Week 18
Study NCT00651690 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection on Day 0
Study NCT04002232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPP-ACP-NaF varnish
Description: calcium phosphate containing fluoride releasing varnish to prevent caries
Study NCT04002232 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CPP-ACP-NaF varnish
Description: calcium phosphate containing fluoride releasing varnish to prevent caries
Study NCT00640016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAT-354 10 mg/kg
Description: CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
Study NCT01287065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF(100mcg)/Vilanterol(25mcg) AM
Description: Inhalation powder
Study NCT01287065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF(100mcg)/Vilanterol(25mcg) PM
Description: Inhalation powder
Study NCT01287065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo AM
Description: Inhalation powder
Study NCT01287065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo AM
Description: Inhalation powder
Study NCT01287065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo PM
Description: Inhalation powder
Study NCT01287065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PM
Description: Inhalation powder
Study NCT02885090 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: In children: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml and 2 PAXgene tubes of 2.5 ml (max 0.8-0.9 ml blood/kg) In parents: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml.
Study NCT05049486 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CT scan
Description: Patients will undergone a pelvic CT scan.
Study NCT01214187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled carbon monoxide
Description: The intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.
Study NCT01214187 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: Room air oxygen concentrations will be administered as placebo
Study NCT01270087 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adalimumab
Description: 40 mg IV every 14 days
Study NCT02587429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education
Study NCT04040400 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intraoperative radiotherapy (IORT)
Description: intraoperative radiotherapy (IORT) during brain tumor resection to establish a maximum tolerated dose (MTD) through a dose-escalation trial using intraoperative radiotherapy (IORT)
Study NCT02691260 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: incentives for dietary self-monitoring
Description: Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application.
Study NCT02691260 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: incentives for interim weight loss
Description: Participants will receive intermittent financial incentives for losing an expected amount of weight based weight obtained weekly.
Study NCT02691260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: incentives for both
Description: Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application and for losing an expected amount of weight based on weight obtained weekly.
Study NCT03798223 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLT
Description: A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
Study NCT03498846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified EA and AMLK
Description: Two pieces of corneal epithelial tissue with 2mmx3mm will be obtained from the fellow eye using femtosecond laser technology. This epithelial autograft (EA) is then ready for transplantation on the disease eye, following the procedure of allogeneic middle lamellar keratoplasty (AMLK).
Study NCT03498846 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LA and AMLK
Description: A 3-clock-hour limbal autograft (LA) will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following the procedure of AMLK.
Study NCT03334409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Given IV
Study NCT03334409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT03334409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT01964807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette, NIDA test type with 16.6 mg nicotine
Description: Smoke a single cigarette for up to 10 minutes
Study NCT01964807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette, NIDA test type with <0.45 mg nicotine
Description: Smoke a single low-nicotine cigarette for up to 10 minutes
Study NCT01964807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic cigarette with 18 mg/ml nicotine
Description: Use electronic cigarette with 18 mg/ml nicotine for 30 minutes
Study NCT01964807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette with no nicotine
Description: Use electronic cigarette with no nicotine for 30 minutes
Study NCT01964807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moist snuff
Description: Use moist snuff for 30 minutes
Study NCT01964807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Smoking
Description: Sham smoking or e-cigarette use consists of puffing on a drinking straw for 10 minutes
Study NCT01964807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondhand cigarette smoke (SHS)
Description: 180-minute exposure to SHS generated by controlled dilution of smoke from machine-smoked cigarettes
Study NCT01964807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditioned, filtered air
Description: Exposure to conditioned, filtered air for 180 minutes
Study NCT01964807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Moist Snuff
Description: Chew gum for 30 minutes
Study NCT00975715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRI476
Description: TRI476 oral suspension doses, based on body weight twice daily
Study NCT00975715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to TRI476
Description: Placebo oral suspension, taken twice daily
Study NCT00975715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benzodiazepines
Description: Benzodiazepines could be used as needed as rescue medication during the duration of the study.
Study NCT00975715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Description: Benzodiazepines could be used as needed as rescue medication during the duration of the study.
Study NCT04209465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDTX-189
Description: Participants will receive a daily, oral dose of BDTX-189 as part of a 3 week cycle.
Study NCT03937726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boiled peanut
Description: Desensitisation using boiled peanut for induction and initial updosing
Study NCT03937726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Defatted roasted peanut flour
Description: Desensitisation using defatted peanut flour for induction and initial updosing
Study NCT03035903 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Not holding, then holding the MedGem®
Description: Subjects will have a RMR measurement taken first while not holding the MedGem®, and then while holding the MedGem®
Study NCT03035903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Not holding, then holding the MedGem®
Description: Subjects will have a RMR measurement taken first while not holding the MedGem®, and then while holding the MedGem®
Study NCT03035903 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holding, then not holding the MedGem®
Description: Subjects will have a RMR measurement taken first while holding the MedGem®, and then while not holding the MedGem®
Study NCT03035903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holding, then not holding the MedGem®
Description: Subjects will have a RMR measurement taken first while holding the MedGem®, and then while not holding the MedGem®
Study NCT01839500 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab
Description: Trastuzumab administered in accordance with routine care practice.
Study NCT03252054 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Screening for memory disorders, attention disorders, and malnutrition
Description: Screening for memory disorders, attention disorders, and malnutrition, using Six-Item Screener, Months of the Year Backwards Test, and NRS-2002 and MNA-SF, respectively.
Study NCT00261846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Part 1, starting dose 400 mg oral, daily dosing in the dose-escalation component.~Part 2, 500 mg oral, continuous, daily dosing.
Study NCT00555542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Patients are taking stable dose of methotrexate and at least 10mg folic acid per week for at least 4 weeks. Rituximab is administrated as 1000mg intravenous infusion on day 1 and day 15. Premedication as standard prescription consists of methylprednisolone 100mg IV, Chlorpheniramine maleate(piriton 10mg IV and oral paracetamol 500mg to be given 30 minutes before each infusion of rituximab. Oral prednisolone 60mg is tob e given from day 1-6 after rituximab infusion and 30mg from day 7-13.
Study NCT01601847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: Once the dietary intake of vitamin D has exceeded 200 IU/Day, the infants will receive placebo until they are 6 months of age adjusted for prematurity
Study NCT01601847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity
Study NCT01660126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH >=0.4 and \<4.6 mU/L, no change to dose; TSH >=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg.
Study NCT01660126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00325039 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: retropubic mid-urethral sling (TVT)
Description: This trial is a comparison of two types of mid-urethral slings. The retropubic mid-urethral mesh sling is used for treatment of stress incontinence; this procedure was less invasive than the fascial sling procedures that were reference standards at the start of the study. Specifically, a synthetic tape is passed transvaginally at the midurethral level through the retropubic space.
Study NCT00325039 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transobturator mid-urethral sling (TVT-O and the Monarc)
Description: This trial is a comparison of two types of mid-urethral slings. The transobturator mid-urethral sling is used for treatment of stress incontinence; this procedure was developed to minimize the potential for bladder and bowel injuries associated with the retropubic sling, since the sling is passed through the obturator canal, avoiding the pelvic organs in the retropubic space.
Study NCT02639468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stroke Volume estimation using electrical impedance tomography
Study NCT00954174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00954174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT00954174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT00954174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00350662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone (L1)
Description: 75 mg/kg body weight daily
Study NCT00350662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desferrioxamine
Description: In combination with deferiprone: 40-50 mg/kg body weight 2-times weekly As single agent: 40-50 mg/kg body weight 5- to 7-times weekly
Study NCT00350662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desferrioxamine
Description: In combination with deferiprone: 40-50 mg/kg body weight 2-times weekly As single agent: 40-50 mg/kg body weight 5- to 7-times weekly
Study NCT00670189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-833923 (XL139)
Description: Capsules, Oral, 30 mg starting; dose escalation, Once daily, 37 days; additional days if receiving benefit
Study NCT02249767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin
Description: Treatment of acne once daily in evening
Study NCT02249767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tretinoin
Description: Treatment of acne once daily in evening
Study NCT04664010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C
Description: Atomized inhalation of 5 million U α-interferon and 2 mL sterilized water, twice a day; 0.2 g arbidol, three times a day, treatment course no more than 10 days; intravenous administration of ribavirin 500 mg, once every 12 hours, treatment course no more than 10 days; intravenous administration of 10 g immunoglobulin C, once a day, 3-5 days. Anti-bacterial infection treatment is given to the patients who have yellow sputum and increased levels of procalcitonin and other bacterial infection specific indicators.
Study NCT04664010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose
Description: Buzhong Yiqi plus and minus formula: 1 dose once, twice a day, taking with warm water. Huhuang Detoxicity Paste: One dose once, twice a day, taking with warm water; Baimu Qingre Jiedu Paste: One dose once, twice a day, taking with warm water; Fumigation/inhalation of Chinese herbs and vitamin C: 30-40 minutes once, 3-7 times a day. Patients take vitamin E capsule and folic acid every day. plus invention 1
Study NCT04664010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment
Description: invention 1 plus invention 2 plus 100 mL of 5% glucose containing vitamin C (10 g/60 kg body mass) is intravenously administered twice a day.
Study NCT04054609 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FAZA PET/MRI scan
Description: PET/MRI scan using radio tracer named 18F-Fluoroazomycin Arabinoside (FAZA) pre and post standard of care endovascular treatment for critical limb ischemia patients
Study NCT03327116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: oral, 15 mg per week, 24 weeks
Study NCT02311998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Given PO
Study NCT02311998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV
Study NCT02736136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: joint observation and video feedback
Study NCT04580797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 IR
Description: Immediate release formulation
Study NCT04580797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 MR1
Description: Modified release formulation 1
Study NCT04580797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 MR2
Description: Modified release formulation 2
Study NCT04580797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 MR3
Description: Modified release formulation 3
Study NCT04580797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study NCT03241212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting
Description: From baseline appointment to 6 month follow up, those participants randomly assigned to the texting intervention will receive a text message every Monday, Wednesday and Friday. Some text messages will be informational only, others will ask the participant for a response to a multiple-choice question with immediate feedback on the answer chosen.
Study NCT02092350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Grazoprevir 100 mg tablet
Study NCT02092350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Elbasvir 50 mg tablet
Study NCT02092350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Grazoprevir
Description: Placebo tablet matched to grazoprevir
Study NCT02092350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Elbasvir
Description: Placebo tablet matched to elbasvir
Study NCT04379050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: Solution for continuous subcutaneous infusion (CSCI).
Study NCT00809211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Study NCT00809211 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis